← Back to Search

Gut Bacteria Analysis for Type 2 Diabetes (DBBIOTE Trial)

N/A

Recruiting

Led By André Marette, PhD

Research Sponsored by Laval University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one week

Awards & highlights

DBBIOTE Trial Summary

This trial will explore the effects of different types of gut bacteria on obese individuals with type 2 diabetes.

Who is the study for?

This trial is for individuals who have been newly diagnosed with type 2 diabetes or those without the disease. Participants should not be taking any oral medications for lowering blood sugar, cholesterol, or blood pressure.Check my eligibility

What is being tested?

The study involves an endoscopy and duodenal biopsy to explore how gut bacteria might influence type 2 diabetes by affecting insulin resistance and glucose tolerance.See study design

What are the potential side effects?

Potential side effects include discomfort from the endoscopy procedure, such as sore throat, bloating, nausea, and risks associated with biopsies like bleeding or infection.

DBBIOTE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one week

This trial's timeline: 3 weeks for screening, Varies for treatment, and one week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Microbial signature

DBBIOTE Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Type 2 Diabetes patientsExperimental Treatment1 Intervention

Upper gut biopsies and lower gut samples

Group II: Non Type 2 Diabetes patientsActive Control1 Intervention

Upper gut biopsies and lower gut samples

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor

420 Previous Clinical Trials

172,687 Total Patients Enrolled

André Marette, PhDPrincipal InvestigatorLaval University

1 Previous Clinical Trials

20 Total Patients Enrolled

Media Library

Endoscopy and duodenal biopsy and sampling Clinical Trial Eligibility Overview. Trial Name: NCT04579900 — N/A

Type 2 Diabetes Research Study Groups: Non Type 2 Diabetes patients, Type 2 Diabetes patients

Type 2 Diabetes Clinical Trial 2023: Endoscopy and duodenal biopsy and sampling Highlights & Side Effects. Trial Name: NCT04579900 — N/A

Endoscopy and duodenal biopsy and sampling 2023 Treatment Timeline for Medical Study. Trial Name: NCT04579900 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for me to get involved in this research?

"This medical experiment is looking for 40 participants with type 2 diabetes mellitus between the ages of 18 to 60. Notably, applicants must meet two qualifications: T2DB de novo or non-T2DB patients."

Answered by AI

Is enrollment for this research still open?

"As per information found on clinicaltrials.gov, this investigation is presently recruiting suitable candidates. The recruitment process was initiated in early February 2021 and the last update to the protocol occurred at the beginning of January 2022."

Answered by AI

How many participants have joined this clinical examination thus far?

"Affirmative. According to the clinicaltrials.gov data, this medical experiment is actively accepting volunteers and has been since February 1st 2021. The study was most recently modified on January 21st 2022 and requires 40 people at a single site."

Answered by AI